AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02935452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GENIE - social networking tool
Description: GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
Study NCT00435591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: ampoule or premix bag
Study NCT00435591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: ampoule or premix bag
Study NCT02618915 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX101
Description: solution for IV infusion
Study NCT01864057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiamine hydrochloride 100 mg
Study NCT03933930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactate-directed therapy
Description: If the lactate level elevates, we transfuse pRBC to increase Hct>30%. If Hct >30%, dopamine infusion starts.
Study NCT03933930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: If SVV>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
Study NCT03279263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLR-1023
Description: MLR-1023 Tablets
Study NCT03279263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablets
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 0.5%w/w
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 0.75%w/w
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 1.0%w/w
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 1.5%w/w
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 2.0%w/w
Study NCT06593730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream 2.5%w/w
Study NCT04162613 — intervention group
Intervention type: OTHER
Intervention: Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation
Description: The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level.
Study NCT04389736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Description: Participants sat in a chair with back, arms and legs supported.
Study NCT04389736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
Study NCT04389736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected maximal intensity of neuromuscular electrical stimulation
Description: Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
Study NCT02411500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
Study NCT00153504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing and Health Study housing rental assistance
Study NCT00153504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard local practice housing assistance
Study NCT00383136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban high-bolus dose regimen
Description: bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
Study NCT00383136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
Study NCT01217957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT03525678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin frozen liquid
Description: Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
Study NCT03525678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin lyophilized powder
Description: Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
Study NCT02633124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edelvaiss Multiline NEO
Description: Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
Study NCT02633124 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Infusion Set
Description: Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
Study NCT03666754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy arm
Description: Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
Study NCT03666754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early endovenous glue embolization arm
Description: Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
Study NCT01582477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 20 mL
Description: EXPAREL 266 mg (undiluted)
Study NCT01582477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL 40 mL
Description: EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
Study NCT02886819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: Whole body vibration
Study NCT04133818 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multidisciplinary education and exercise therapy program
Description: Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation
Study NCT00671736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moli1901
Description: 2,5 ml inhalation solution, 8 weeks treatment period
Study NCT00671736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moli1901 placebo
Description: 2,5 ml placebo solution, 8 weeks treatment period
Study NCT00403377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
Study NCT02237417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Oral antipsychotics
Description: A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
Study NCT02237417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM aripiprazole once monthly
Description: A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
Study NCT02237417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: A total of 15 healthy controls will participate in the study and will not receive medication
Study NCT03140241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth
Study NCT03365271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage
Description: Applying a drain tube during TKA procedure
Study NCT03365271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-drainage
Description: No drain tube will be applied during TKA procedure
Study NCT01184092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
Study NCT01184092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
Study NCT01184092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
Study NCT03745612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Study NCT03745612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
Study NCT00587522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDO Full-thickness Plicator
Description: The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
Study NCT01295814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Study NCT01295814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inactive drug
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Study NCT06176079 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized (HP) 13C
Description: A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
Study NCT06176079 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized 13C-Urea
Description: Given intravenously (IV)
Study NCT06176079 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging procedure
Study NCT06176079 — intervention group
Intervention type: PROCEDURE
Intervention: Saline Flush
Description: A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
Study NCT00758667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
Study NCT01546610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insoles intervention
Description: EVA insole with arch support and bar retrocapital
Study NCT01546610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo insole
Description: EVA insole flat
Study NCT02984813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlaucoHealth
Description: Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
Study NCT02984813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlaucoSelect
Description: Containing curcumin, bilberry extract, and grape seed extract
Study NCT02984813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredients
Study NCT01256788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euflexxa
Description: 4 injections of 2ml of Euflexxa
Study NCT01256788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 4 injections of 3 ml of sterile saline
Study NCT01203202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomipramine
Description: 15mg and 30mg on demand
Study NCT01203202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine
Description: 15mg and 30mg on demand
Study NCT03574584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1562
Description: Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
Study NCT03574584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
Study NCT03574584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0165-1562)
Description: Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
Study NCT01217957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT01217957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT02074553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F03 (Reference)
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
Study NCT02074553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F07 (Test)
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
Study NCT02074553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F08 (Test)
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
Study NCT04165577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole
Study NCT04165577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 1-Hz rTMS targeting frontal pole
Study NCT02074553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro542-4802/F14 (Test)
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
Study NCT00500162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tri-Luma Maintenance regimen
Study NCT01487408 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
Study NCT00367887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron
Description: SC injection, weight based dosing, weekly, 48 weeks
Study NCT00367887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REBETOL
Description: Capsules, weight based dosing, Q12 hrs daily, 48weeks
Study NCT00367887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCV 796
Description: Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prezista
Description: once daily
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prezista
Description: once daily
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norvir
Description: once daily
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvir
Description: once daily
Study NCT04165577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sham rTMS
Description: sham rTMS targeting frontal pole
Study NCT04165577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS targeting frontal pole
Study NCT02785549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg/8hours
Study NCT02785549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg/8hours
Study NCT02785549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g/8 hours
Study NCT02785549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g/8 hours
Study NCT02785549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Description: 875mg/125mg/8 hours
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay
Description: once daily
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: once daily
Study NCT01047358 — intervention group
Intervention type: DRUG
Intervention: Aromasin
Description: 25 mg table QD
Study NCT00948376 — intervention group
Intervention type: GENETIC
Intervention: IFT80 screening
Description: Natural History
Study NCT02746653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TroClose1200(TM)
Description: Creation of access port and closure it by the same device, TroClose1200(TM)
Study NCT02252003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scales testing
Study NCT03258385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 fortified UHT milk
Description: Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
Study NCT03258385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain UHT milk
Description: Daily intake of 200 mL of plain UHT milk
Study NCT02303496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Cream
Description: Cream Containing Platelet Rich Plasma and Oleaginous Base
Study NCT02303496 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Sterile Water Cream
Description: Cream Containing Sterile Water and Oleaginous Base
Study NCT00696072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg once daily, up to 2 years
Study NCT00696072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Tablets, Oral, 2.5 mg, once daily, up to 2 years
Study NCT00000385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium 600 mg to 2700 mg per day
Study NCT00000385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kivexa
Description: once daily
Study NCT02486133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Descovy
Description: once daily
Study NCT03130803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insufficient Sleep
Description: 2 days with 5 hour sleep opportunity per day